Presentation is loading. Please wait.

Presentation is loading. Please wait.

SWISS TUMOR BOARD Pancreatic Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Published byMerry Gaines Modified over 9 years ago

Similar presentations

Presentation on theme: "SWISS TUMOR BOARD Pancreatic Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne."— Presentation transcript:

1 SWISS TUMOR BOARD Pancreatic Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne

2 Case #1 J. Metzger Male patient, 55-yr-old G3, pT2pN1 (1+/16), R0 (close margin) Adjuvant ttt?, Cx alone?, Cx and RT?

3 Case #1 Short literature review on adjuvant CT/RT GITSG study including 43 + 32 patients (Kalser, Arch Surg 1985; Cancer 1987) = RT/CT (40 Gy/5FU) better than observation (20 vs. 11 months median survival) EORTC 40891 study including 114 patients (Klinkenbijl, Ann Surg 1999) = No difference RT/CT (split course 40 Gy/5FU) vs. observation (17 vs.13 months median survival) ESPAC-1 study including 289 patients (pooled analysis 541 patients) (Neoptolemos, Lancet 2001, NEJM 2004) = 2x2 factorial design; CT vs. RT/CT vs. CT/RT+CT vs. observation. RT worsens the outcome whereas chemo. increases it (very complex study with a lot of criticism) CONKO study including 368 R0/R1 patients (Oettle, JAMA 2007, ProcASCO 2008) = gemcitabine vs. observation (23 vs 20 months median survival; 21 vs. 9% OS; gemcitabine better). Very clean data. RTOG 9704 including 388 pancreatic head patients (Regine, JAMA 2008) compared conventional RT/CT (5FU) vs. 3-wk gemcitabine + RT/CT (5FU) + 3 mo. gemcitabine. Gemcitabine arm better (20.5 vs. 17 months median survival). Meta-analyses assessing the impact of chemotherapy (Stocken, BJC 2005; Butturini, Arch Surg 2008): Chemotherapy is better, and more pronounced in negative-margin patients. NCCN guidelines and current evidence: waiting the ESPAC-3 results (observation vs. leucovorin/5FU vs. gemcitabine), the standard is CONKO or RTOG 9704 type treament

4 EORTC 40891 study

5 Case #1 Short literature review on adjuvant CT/RT GITSG study including 43 + 32 patients (Kalser, Arch Surg 1985; Cancer 1987) = RT/CT (40 Gy/5FU) better than observation (20 vs. 11 months median survival) EORTC 40891 study including 114 patients (Klinkenbijl, Ann Surg 1999) = No difference RT/CT (split course 40 Gy/5FU) vs. observation (17 vs.13 months median survival) ESPAC-1 study including 289 patients (pooled analysis 541 patients) (Neoptolemos, Lancet 2001, NEJM 2004) = 2x2 factorial design; CT vs. RT/CT vs. CT/RT+CT vs. observation. RT worsens the outcome whereas chemo. increases it (very complex study with a lot of criticism) CONKO study including 368 R0/R1 patients (Oettle, JAMA 2007, ProcASCO 2008) = gemcitabine vs. observation (23 vs 20 months median survival; 21 vs. 9% OS; gemcitabine better). Very clean data. RTOG 9704 including 388 pancreatic head patients (Regine, JAMA 2008) compared conventional RT/CT (5FU) vs. 3-wk gemcitabine + RT/CT (5FU) + 3 mo. gemcitabine. Gemcitabine arm better (20.5 vs. 17 months median survival). Meta-analyses assessing the impact of chemotherapy (Stocken, BJC 2005; Butturini, Arch Surg 2008): Chemotherapy is better, and more pronounced in negative-margin patients. NCCN guidelines and current evidence: waiting the ESPAC-3 results (observation vs. leucovorin/5FU vs. gemcitabine), the standard is CONKO or RTOG 9704 type treament

6 ESPAC-1 study, Lancet 2001

7 ESPAC-1 trial New Engl J Med 2004

8 Case #1 Short literature review on adjuvant CT/RT GITSG study including 43 + 32 patients (Kalser, Arch Surg 1985; Cancer 1987) = RT/CT (40 Gy/5FU) better than observation (20 vs. 11 months median survival) EORTC 40891 study including 114 patients (Klinkenbijl, Ann Surg 1999) = No difference RT/CT (split course 40 Gy/5FU) vs. observation (17 vs.13 months median survival) ESPAC-1 study including 289 patients (pooled analysis 541 patients) (Neoptolemos, Lancet 2001, NEJM 2004) = 2x2 factorial design; CT vs. RT/CT vs. CT/RT+CT vs. observation. RT worsens the outcome whereas chemo. increases it (very complex study with a lot of criticism) CONKO study including 368 R0/R1 patients (Oettle, JAMA 2007, ProcASCO 2008) = gemcitabine vs. observation (23 vs 20 months median survival; 21 vs. 9% OS; gemcitabine better). Very clean data. RTOG 9704 including 388 pancreatic head patients (Regine, JAMA 2008) compared conventional RT/CT (5FU) vs. 3-wk gemcitabine + RT/CT (5FU) + 3 mo. gemcitabine. Gemcitabine arm better (20.5 vs. 17 months median survival). Meta-analyses assessing the impact of chemotherapy (Stocken, BJC 2005; Butturini, Arch Surg 2008): Chemotherapy is better, and more pronounced in negative-margin patients. NCCN guidelines and current evidence: waiting the ESPAC-3 results (observation vs. leucovorin/5FU vs. gemcitabine), the standard is CONKO or RTOG 9704 type treament

9 CONKO study, JAMA 2007

10 Neuhaus, ASCO 2008

11 Case #1 Short literature review on adjuvant CT/RT GITSG study including 43 + 32 patients (Kalser, Arch Surg 1985; Cancer 1987) = RT/CT (40 Gy/5FU) better than observation (20 vs. 11 months median survival) EORTC 40891 study including 114 patients (Klinkenbijl, Ann Surg 1999) = No difference RT/CT (split course 40 Gy/5FU) vs. observation (17 vs.13 months median survival) ESPAC-1 study including 289 patients (pooled analysis 541 patients) (Neoptolemos, Lancet 2001, NEJM 2004) = 2x2 factorial design; CT vs. RT/CT vs. CT/RT+CT vs. observation. RT worsens the outcome whereas chemo. increases it (very complex study with a lot of criticism) CONKO study including 368 R0/R1 patients (Oettle, JAMA 2007, ProcASCO 2008) = gemcitabine vs. observation (23 vs 20 months median survival; 21 vs. 9% OS; gemcitabine better). Very clean data. RTOG 9704 including 388 pancreatic head patients (Regine, JAMA 2008) compared conventional RT/CT (50.4 Gy/5FU) vs. 3-wk gemcitabine + RT/CT (5FU) + 3 mo. gemcitabine. Gemcitabine arm better (20.5 vs. 17 months median survival). Meta-analyses assessing the impact of chemotherapy (Stocken, BJC 2005; Butturini, Arch Surg 2008): Chemotherapy is better, and more pronounced in negative-margin patients. NCCN guidelines and current evidence: waiting the ESPAC-3 results (observation vs. leucovorin/5FU vs. gemcitabine), the standard is CONKO or RTOG 9704 type treament

12 RTOG 9704 study Regine, JAMA 2008

13 Case #1 J. Metzger Male patient, 55-yr-old G3, pT2pN1 (1+/16), R0 (close margin) Adjuvant ttt?, Cx alone?, Cx and RT? GITSG (RT/CT better than observation) EORTC (RT/CT vs. Observation) = no difference ESPAC-1 (CT vs. RT/CT vs. CT/RT+CT vs. observation) = RT group worse CONKO (gemcitabine vs. observation) = gemcitabine better RTOG 9704 (conventional RT/CT vs. gemcitabine + RT/CT + gemcitabine) = gemcitabine arm better (borderline significance) Conlusion: pT2pN1 R0; therefore adjuvant gemcitabine would be the right decision (CONKO) (young patient = RTOG 9704? not accepted in Europe) NCCN guidelines: RT/CT vs. gemcitabine, both OK

Download ppt "SWISS TUMOR BOARD Pancreatic Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne."

Similar presentations

Pancreatic cancer perspectives Is there any improvement ? Pancreatic cancer perspectives Is there any improvement ?

Pancreatic cancer perspectives Is there any improvement ? Pancreatic cancer perspectives Is there any improvement ?
Advances and Emerging Therapy for Lung Cancer

Advances and Emerging Therapy for Lung Cancer
Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.
Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148

Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148
Radiation Therapy for Pancreatic Cancers Eyad Abu-Isa, M.D. Assistant Professor, Radiation Oncology University of Michigan/Providence Cancer Institute.

Radiation Therapy for Pancreatic Cancers Eyad Abu-Isa, M.D. Assistant Professor, Radiation Oncology University of Michigan/Providence Cancer Institute.
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.

Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.
NSCLC Pancoast tumor Swiss tumor board Bern – 26.3.2009 Dr. Christian Monnerat Département Pluridisciplaire d’Oncologie – Hôpital Neuchâtelois Service.

NSCLC Pancoast tumor Swiss tumor board Bern – Dr. Christian Monnerat Département Pluridisciplaire d’Oncologie – Hôpital Neuchâtelois Service.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
MRC CR07: 5x5 TME vs. TME RCT in 3y Preop. RT + OP (n=674)

MRC CR07: 5x5 TME vs. TME RCT in 3y Preop. RT + OP (n=674)
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Upper GI Cancers: Risk Stratification and Treatment Selection David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer.

Upper GI Cancers: Risk Stratification and Treatment Selection David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer.
Lung Cancer R. Zenhäusern. Lung cancer: Epidemiology n Most common cancer in the world –2./ 3. most cancer in men / women 1.2 million new cases / year.

Lung Cancer R. Zenhäusern. Lung cancer: Epidemiology n Most common cancer in the world –2./ 3. most cancer in men / women 1.2 million new cases / year.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Similar presentations

Ads by Google